Global Urethral Stricture Treatment Market – Drivers
Increasing inorganic strategies such as approvals by the key market players from the regulatory authorities is expected to drive the global urethral stricture treatment market growth over the forecast period. For instance in February 2022, Laborie, a diagnostic and therapeutic medical technology company, announced that the Therapeutic Goods Administration (TGA) regulation authority in Australia has approved the use of Optilume, a urethral drug coated balloon (DCB) technology for the treatment of anterior urethral stricture.
Global Urethral Stricture Treatment Market: Restraint
High Cost of the Treatment
Urethral stricture treatment requires highly efficient & technologically advanced procedures. Technologically advanced procedures offer fast recovery with no down time and reduces recurrence. However, high cost of surgical procedures is expected to hamper growth of the market, as individuals in lower middle income economies cannot afford the treatment. According to the Elsevier , the cost of first treatment of Direct Vision Internal Urethrotomy (DVIU) is US$ 3,375.0, and the cost of second term treatment of DVIU is US$ 7,522.5 that is very expensive for patients in low and middle income countries. The cost of the treatment could be reduced by making of surgical intruments in house
Restraints & Challenges: |
|
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients